BMC cardiovascular disorders|2026|Musa E, Musa A
Review
PMID: 41906074
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: Bariatric surgery and pharmacotherapy represent two major strategies for the treatment of obesity. Sleeve gastrectomy (SG) is the most widely performed surgical procedure and is supported by long-term evidence, while semaglutide, a glucag…
IMPORTANCE: Patients with diabetes and a history of major adverse limb events (MALEs) are at an increased risk of cardiovascular and limb-related complications; however, effective glucose-lowering therapies for secondary prevention in this population…
A 38-year-old man with poorly controlled type 2 diabetes mellitus and arterial hypertension on semaglutide presented with acute, painless, vision loss in the left eye. Ophthalmic examination revealed optic disc edema (ODE) in the left eye and optic d…
AIM: Coronary artery calcium (CAC) scoring is observed to improve risk stratification for major adverse cardiovascular events (MACE). Semaglutide, a recently introduced anti-obesity drug, is very effective, but wider use is limited due to high costs.…
Limited available data indicate that glucagon-like peptide-1 (GLP-1) medications may significantly reduce weight and binge-eating symptoms among patients with binge-eating disorder. However, experts express concern about the potential for GLP-1 medic…
The global rise in obesity and depression, two highly prevalent and often comorbid disorders has intensified interest in the gut–brain axis as a shared biological link. Mounting evidence indicates that the gut microbiota profoundly influences both me…
A decline in mortality due to heart failure (HF) with reduced ejection fraction (HFrEF) has been attributed to effective guideline-directed medical therapies. But few effective therapies are available for HF with preserved ejection fraction (HFpEF),…
INTRODUCTION: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used for weight management and type 2 diabetes, but reports of reduced skin laxity and volume have raised aesthetic concerns. This study evaluates the first integrated ski…
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a newly defined clinical condition characterized by hepatic steatosis in the presence of one or more cardiometabolic risk factors (CMRFs), such as obesity, type 2 diabetes, or dyslip…
The year 2025 saw major advances in gastroenterology and hepatology. Having long been overshadowed by other chronic viral hepatitis, Hepatitis D now benefits from new therapeutic options, including bulevirtide, offering markedly improved clinical pro…
Peripheral artery disease affects approximately 236 million persons worldwide and is diagnosed with an ankle-brachial index of less than 0.90. Among older persons, 3.3% of those without peripheral artery disease, 18.1% with mild disease, and 52.0% wi…
BACKGROUND: Obesity plays a pivotal and modifiable role in the development and progression of type 2 diabetes mellitus (T2DM). Clinicians increasingly use lower doses of liraglutide (1.2 mg and 1.8 mg) to achieve clinically meaningful weight loss whi…
This article responds to Ryan's and Savulescu's claim that semaglutide enhances autonomy by reducing problematic desires. Drawing on Frankfurt's hierarchical model of autonomy, this article argues that pharmacological alignment between first-order an…
BACKGROUND: People with diabetes have an elevated risk of developing depression, anxiety, and suicide. GLP-1 receptor agonists are licensed to treat diabetes and obesity, but data on whether these medications alleviate or exacerbate anxiety, depressi…
AIMS: To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real-world clinical pract…
A sensitive and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1…
Type 2 diabetes and obesity impact billions of people and the global prevalence is only growing. Current treatment options, which include pharmacotherapy, e.g., GLP-1 receptor agonists (GLP-1RA) and bariatric surgical approaches have limitations. GLY…